📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 17:09
225 analysed today
FollowTelegram
225
Today
149,626
All-time analysed
42,906
Positive
6,661
Negative
91,382
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Q1 Cons. Revenue Up 16.6% YoY to Rs 39.84 Cr, Net Profit Declines 7.0% to Rs 4.67 Cr
Gennex Laboratories reported consolidated revenue from operations of Rs 39.84 Cr for Q1 FY27 (quarter ended June 30, 2026), an increase of 16.57% YoY compared to Rs 34.18 Cr in Q1 FY26, though down 34.64% QoQ from Rs 60.96 Cr. Consolidated net profit for the quarter stood at Rs 4.67 Cr, down 6.98% YoY from Rs 5.02 Cr in Q1 FY26 and up 4.66% QoQ from Rs 4.46 Cr. Basic EPS for the quarter was reported at Rs 0.192 compared to Rs 0.217 in the year-ago period. Standalone sales were driven primarily by the domestic market at Rs 25.37 Cr, followed by export markets led by Colombia (Rs 3.51 Cr) and Egypt (Rs 2.54 Cr).
Confidence: HIGH
What changedGennex Laboratories reported its unaudited standalone and consolidated Q1 FY27 financial results showing YoY top-line growth but lower net profitability.
Why it mattersDemonstrates moderate YoY top-line expansion in bulk drugs and intermediates, though profit margins remain compressed relative to the prior-year quarter.
Consolidated Revenue (Q1): Rs 39.84 crConsolidated Net Profit (Q1): Rs 4.67 crConsolidated EPS (Q1): Rs 0.192Quarterly Revenue vs TTM Revenue: ~22.5%
📅 Short termLikely neutral reaction as top-line growth is offset by a slight YoY net profit contraction and sequential revenue normalization.
📈 Long termLimited; operational performance depends on expanding active pharmaceutical ingredient/bulk drug volumes and sustained export market penetration.
⚠ Risk flags
- Sequential quarterly revenue volatility (fell ~34.6% QoQ from Q4 FY26).
- Geographic concentration in top export markets like Colombia and Egypt.
Key Highlights
Consolidated revenue from operations grew 16.57% YoY to Rs 39.84 Cr (3,984.17 Lacs) vs Rs 34.18 Cr in Q1 FY26.
Consolidated PAT declined 6.98% YoY to Rs 4.67 Cr (466.64 Lacs) vs Rs 5.02 Cr in Q1 FY26.
Consolidated Basic and Diluted EPS stood at Rs 0.192 versus Rs 0.217 in Q1 FY26.
Standalone domestic revenue was Rs 25.37 Cr, while top export geographies were Colombia (Rs 3.51 Cr) and Egypt (Rs 2.54 Cr).
👀 What to Watch
Track sequential revenue stability over upcoming quarters and monitor operating margin trends given higher raw material and other operating costs.
Gennex Labs Q1 Cons PAT at ₹4.67 Cr (-7% YoY); Revenue Up 16.6% to ₹39.84 Cr
Gennex Laboratories reported consolidated revenue from operations of ₹39.84 Cr for Q1 FY27, up 16.6% YoY compared to ₹34.18 Cr in Q1 FY26, but down 34.6% sequentially from ₹60.96 Cr in Q4 FY26. Consolidated net profit for the quarter stood at ₹4.67 Cr, down 7.0% YoY from ₹5.02 Cr, though slightly higher sequentially vs ₹4.46 Cr. Consolidated basic EPS came in at ₹0.192 compared to ₹0.217 in the year-ago quarter. The standalone business contributed revenue of ₹34.68 Cr and net profit of ₹3.96 Cr.
Confidence: HIGH
What changedGennex Laboratories approved and reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Why it mattersTop-line expanded YoY on stronger domestic and select export demand, though higher total expenses led to a mild contraction in net profitability.
Consolidated Revenue (Q1): ₹39.84 CrConsolidated PAT (Q1): ₹4.67 CrConsolidated Basic EPS: ₹0.192Standalone Revenue (Q1): ₹34.68 CrQ1 Revenue vs TTM Revenue: ~22.5%
📅 Short termThe market is likely to view the earnings as neutral-to-mixed given top-line YoY expansion offset by lower sequential revenue and mild YoY profit contraction.
📈 Long termLimited structural change from routine quarterly earnings; long-term performance hinges on capacity ramp-ups and margin stabilization.
⚠ Risk flags
- Sequential top-line volatility (₹39.84 Cr vs ₹60.96 Cr in Q4 FY26)
- Relatively low promoter holding of 23.6%
Key Highlights
Consolidated revenue from operations grew 16.6% YoY to ₹39.84 Cr (₹3,984.17 Lakhs) from ₹34.18 Cr in Q1 FY26
Consolidated PAT fell 7.0% YoY to ₹4.67 Cr (₹466.64 Lakhs) from ₹5.02 Cr in Q1 FY26
Standalone revenue from operations reached ₹34.68 Cr compared to ₹25.64 Cr in Q1 FY26
India business generated standalone revenue of ₹25.37 Cr, followed by Colombia at ₹3.51 Cr and Egypt at ₹2.54 Cr
Consolidated diluted EPS for the quarter was ₹0.192 vs ₹0.206 in Q1 FY26
👀 What to Watch
Track the sustainability of operating profit margins and export sales momentum across key geographies in upcoming quarters.
